Human isotope fractional absorption studies comparing chelated Magnesium Glycinate vs. Citrate vs. 4% Oxide, CYP2R1/CYP27B1 magnesium-dependent Vitamin D3 activation trials, and Metformin-induced Vitamin B12 holotranscobalamin depletion. Explore 4,328 indexed studies and multi-trial syntheses with verified PubMed PMIDs, participant sample sizes (N), and Absolute vs. Relative Risk numbers.
The Plain-English Receipt: Only 1.2% of prediabetic adults on Tirzepatide progressed to Type 2 diabetes over 3.4 years vs. 19.3% on placebo (Absolute Risk Reduction = 18.1% • Number Needed to Treat = 6).
Exit interviews were conducted with 29 of 159 patients enrolled in XTEND-1 (mean [range] age 40 [16-73] years).
The study shows that the two drugs had similar bioequivalence and safety.
We observed decreased CTX, decreased PINP and increased lumbar spine BMD after two years of testosterone treatment.
These results suggest safe use of daridorexant in patients with mild to moderate OSA.
TRT normalized serum testosterone levels, improved blood sugar control and endothelial function while exerting no ill effects on the study population.
Salt supplementation significantly reduced the MAP lowering effects of telmisartan (P<0.05).
Our data also suggest that the ability of blood-pressure-lowering treatment to inhibit cardiac apoptosis is independent of its blood-pressure-lowering efficacy.
Longitudinal muscle mass loss emerged as a predictive factor for both OS and HRQoL in aPDAC patients undergoing chemotherapy, while a low SMI at diagnosis did not provide prognostic value.
12%), thrombocytopenia (50% vs.
The use of a low dose of remifentanil before cord clamping for a Cesarean section appears to be safe both for the mother and the preterm newborn, but it does not improve maternal or neonatal outcomes.
Rosuvastatin exposure was moderately higher with filgotinib getting both at the same time-GLSM ratios (90% CI), 1.68 (1.43-1.97) for C max ; 1.42 (1.30-1.57) for AUC inf -but this was not considered clinically relevant.
Limited survival benefit in the Japanese subgroup can be attributed to small patient numbers and to baseline imbalances observed between treatment arms, with more patients in the venetoclax plus low-dose cytarabine arm presenting.
Conclusion: Meloxicam IV was generally well tolerated and associated with decreased opioid consumption, lower resource utilization and functional benefits.
Patients with comorbid depression and trouble sleeping who experienced the first onset of both disorders in childhood are less responsive to the treatments offered herein than are those.
Estradiol, but not progesterone or T, is a major regulator of VLDL-TG metabolism.
CETP activity was reduced by 10.3% and 26.4% with the low and high dose of atorvastatin.
Dapagliflozin-statin combination therapy appears potentially beneficial for heart disease patients without affecting drug levels, though larger studies are needed to confirm.
Protein, adenovirus-vector or mRNA vaccine boosters were equally well tolerated and immunogenic against ancestor SARS-CoV-2 and Omicron sub-lineages in fully primed adults with 0-2 prior boosters.
The safety profile of upadacitinib through 5 years was consistent with the known safety profile of upadacitinib, with no new safety risks.
Perioperative mFOLFOX6 may be an insufficient treatment to improve survival of lower rectal cancer with lateral pelvic lymph node metastasis.
Treatment-emergent side effects were similar in patients who converted to LCPT and in those who remained on IR-Tac.
Aortic blood pressures (median systolic 115 mm Hg and diastolic 76 mm Hg) and augmentation index (median 33%) did not differ among women across prior treatment assignment.
In this 4-year prospective assessment of recently menopausal women, MHT did not significantly alter RHI when compared to placebo.
The present study demonstrated that on-demand T+5-HT ra is a potentially promising treatment for women with HSDD, particularly for those women who are prone to sexual inhibition.
No side effects were reported with placebo.
The results imply that telmisartan could treat both the blood flow and heart rate and metabolic aberrations seen in patients with the metabolic syndrome, improving insulin resistance and glucose intolerance at least partly...
Estradiol cannot be considered as an effective treatment in postmenopausal women with mild to moderate depression.
In children with FC and comorbid NDD, linaclotide 72 µg once daily was associated with improved constipation outcomes, high staying on track with medication, and a well-tolerated safety profile, similar to that seen in the...
The infusion of NaCl compared to glucose added to diuretic therapy led to significantly higher diuresis, natriuresis, and lower loop diuretic use, driven by lower sodium avidity and inhibition of proximal tubular sodium...
Exit interview results support the content validity of the COVID-19 symptom diary and global impression items, with the 14 symptoms included in the diary reflecting the most commonly experienced COVID-19 symptoms.
Traditional health headlines often exaggerate findings by reporting only Relative Risk Reduction—for example, claiming a drug cuts risk by 50% when the event rate dropped from 2% to 1% (an Absolute Risk Reduction of just 1.0 percentage point, meaning 100 patients must take the drug for 1 person to benefit, or NNT = 100). On dotMD, every flagship study breakdown reports both Relative Risk and Absolute Risk alongside the exact sample size (N) and trial duration.
Every study on dotMD displays its exact Study Design Tier at the top of the card (Phase 3 Randomized Trial, Randomized Controlled Trial, Meta-Analysis & Systematic Review, Multi-Trial Clinical Evidence Synthesis, Journal Watch Cohort, or FDA Safety Alert) along with the human participant count (N). Preclinical mouse or cell-culture data is never presented as human clinical proof.
Arbitrary 0-to-100 rigor scores obscure what actually makes a study trustworthy. Instead of synthetic scores, dotMD surfaces the verifiable primary evidence signals: exact NCBI PubMed IDs (PMID), ClinicalTrials.gov registration numbers (NCT), double-blind vs. crossover design, sample size (N), p-values / Hazard Ratios, and study limitations.
Medical research is only useful if you can act on it safely with your clinician. Every flagship research synthesis links directly to the parent Condition diagnostic cutoff guide, the Medication FDA DailyMed & CMS NADAC wholesale price ledger, the Supplement elemental weight decoder, and our High-CPT-Volume Specialist Directory.
